Santen Pharmaceutical Co., Ltd.
SNPHY
Other OTC11.93
USD
+0.71
- -
ISIN
US80287P1003
CUSIP
80287P100
Return %
Stock
S&P500
1Y
2.32
26.57
3Y
29.96
76.60
5Y
-9.89
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Takeshi Ito
- Full Time Employees
- 3,744
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Grand Front Osaka Tower A Osaka Japan 530-8552
- IPO Date
- Aug 31, 2011
- Website
- santen.com
- Similar Companies
- Business
- Santen Pharmaceutical Co., Ltd. (SNPHY) is a global pharmaceutical company specializing in the research, development, manufacturing, marketing and sales of prescription ophthalmic pharmaceuticals, over-the-counter eye care products and medical devices focused on ophthalmology. Founded in 1890 and headquartered in Osaka, Japan, the company offers a portfolio exceeding 70 products addressing glaucoma, dry eye disease, ocular allergies, uveitis, myopia, ptosis, meibomian gland dysfunction and retinal disorders; key offerings include tafluprost/timolol maleate combination eye drops, ciclosporin ophthalmic emulsion for vernal keratoconjunctivitis, latanoprost emulsion, epinastine hydrochloride for allergic conjunctivitis, netarsudil mesylate/latanoprost fixed-dose combination, sepetaprost prostaglandin analogue, atropine sulfate for juvenile myopia, olodaterol hydrochloride for dry eye and sirolimus ophthalmic suspension for Fuchs endothelial corneal dystrophy. Santen operates in over 60 countries across Japan, China, Asia, Europe, the Middle East, Africa and the Americas, with prescription pharmaceuticals comprising the majority of revenue alongside over-the-counter products and surgical devices. In recent developments, Santen launched SETANEO Ophthalmic Solution 0.002% in Japan in October 2025 for glaucoma and ocular hypertension treatment, resumed shipments of DIQUAS LX Ophthalmic Solution 3% for dry eye in December 2025 following a temporary suspension and announced a collaboration with the Singapore Eye Research Institute in December 2025 to advance disease-modifying therapies for major eye diseases. The company entered a licensing agreement with Cloudbreak Pharma in September 2024 for a topical pterygium treatment in Japan and beyond, secured exclusive commercialization rights in China for Arctic Vision's ARVN001 uveitic macular edema therapy via an USD 85 million deal in late 2024 and progressed with RemeGen on RC28-E intravitreal injection, including BLA acceptance in China for diabetic macular edema in September 2025.
Santen Pharmaceutical (OTCMKTS:SNPHY) & Otsuka (OTCMKTS:OTSKY) Financial Review
Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update